Simultaneous Determination of 11 Commonly used Cephalosporin Antibiotics Residue by High Performance Liquid Chromatography - Diode Array Detectors in Pharmaceutical Waste Water - A Tool for Controlling One of the Source of Antibiotic Resistance

11 commonly used Cephalosporin drugs from 1st, 2nd & 3rd Generation in wastewater from Cephalosporin Antibiotics Manufacturing plant is developed, validated and proposed for routine analysis of wastewater collected from waste water pre-treatment plant (wwptp). The determined residues included the routinely manufactured cephalosporin drugs for the treatment as β-Lactams Antibiotic drugs like Cefepime, Cefadroxil, Ceftazidime, Cephradine, Cefaclor, Cefotaxime, Ceftibuten, Ceftriaxone, Cefixime, Cefuroxime Axetil and Cefpodoxime proxetil. A gradient program was developed with Xterra RP-18 (250 cm x 4.6 mm, 5 µm) column as stationary phase. All cephalosporin molecules were selective and separated with a 0.2 M Tetra-butyl Ammonium Hydroxide (TBAH) buffer and Acetonitrile in the ratio of 85:15 V/V (Solution-A) and 25:75 V/V (Solution-B), pH 6.8 was adjusted with O-phosphoric acid into the buffer solution as the mobile phase at flow of 1.2 mL min- 1 with a UV detection at 254 nm using DAD. All peaks eluted within 60 minutes gradient run. The system suitability parameters such as theoretical plate count, tailing and resolution between the closest peaks were within the limit. The method was validated following all criteria regarding ICH (Q2) guidelines. Calibrations were linear over the concentration range of 0.5–150 µg mL-1 as indicated by correlation coefficient (r) of 0.999. The developed method can be the tool for determining the Cephalosporins residue as routine quantitative analysis of waste water discharged from the Antibiotic manufacturing plant. Keywords: Cephalosporins, Waste water, Method validation, Antibiotic Resistance, Antibiotic manufacturing plan

Disease characteristics and serological responses in patients with differing severity of COVID-19 infection: A longitudinal cohort study in Dhaka, Bangladesh.

BackgroundCOVID-19 caused by SARS-CoV-2 ranges from asymptomatic to severe disease and can cause fatal and devastating outcome in many cases. In this study, we have compared the clinical, biochemical and immunological parameters across the different disease spectrum of COVID-19 in Bangladeshi patients.Methodology/principal findingsThis longitudinal study was conducted in two COVID-19 hospitals and also around the community in Dhaka city in Bangladesh between November 2020 to March 2021. A total of 100 patients with COVID-19 infection were enrolled and classified into asymptomatic, mild, moderate and severe cases (n = 25/group). In addition, thirty age and sex matched healthy participants were enrolled and 21 were analyzed as controls based on exclusion criteria. After enrollment (study day1), follow-up visits were conducted on day 7, 14 and 28 for the cases. Older age, male gender and co-morbid conditions were the risk factors for severe COVID-19 disease. Those with moderate and severe cases of infection had low lymphocyte counts, high neutrophil counts along with a higher neutrophil-lymphocyte ratio (NLR) at enrollment; this decreased to normal range within 42 days after the onset of symptom. At enrollment, D-dimer, CRP and ferritin levels were elevated among moderate and severe cases. The mild, moderate, and severe cases were seropositive for IgG antibody by day 14 after enrollment. Moderate and severe cases showed significantly higher IgM and IgG levels of antibodies to SARS-CoV-2 compared to mild and asymptomatic cases.Conclusion/significanceWe report on the clinical, biochemical, and hematological parameters associated with the different severity of COVID-19 infection. We also show different profile of antibody response against SARS-CoV-2 in relation to disease severity, especially in those with moderate and severe disease manifestations compared to the mild and asymptomatic infection